logo
  

Takeda To Stop Phase 2 Studies Of Investigational Oral Orexin Agonist TAK-994

Takeda Pharmaceutical Company Limited (TAK) said that a safety signal has emerged in Phase 2 studies of TAK-994, an investigational oral orexin agonist. As an immediate precautionary measure, the company has suspended dosing of patients and has decided to stop both Phase 2 studies early. It allows for the timely interpretation of the benefit /risk profile of TAK-994 and to determine next steps for the program.

Takeda said it is committed to bringing safe and effective treatments to patients with narcolepsy. The company is working to quickly assess the totality of available data to inform the further development of TAK-994.

Takeda is committed to advancing its multi-asset orexin franchise including the oral orexin agonist TAK-861, which is currently in Phase 1 development.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of LM Ericsson were gaining more than 7 percent in Swedish trading as well as in pre-market activity on Nasdaq, after the telecom equipment maker reported Tuesday higher profit and sales in its fourth quarter with strong demand. Further, the company lifted its full-year dividend, and maintained targets for fiscal 2022 EBIT growth as well as long-term target of EBITA margin. Twitter Inc. said it is expanding engineering center in Singapore, its Asia Pacific headquarters. The number of engineers there will be doubled to over 100 staff in 2023. Focused on product innovations and improvements, the new hires will work from Singapore on global initiatives for Twitter. These new technical hires will span roles in engineering, data science, machine learning and product... The U.S. Food and Drug Administration (FDA) has granted approval and reissued the revised Emergency Use Authorization (EUA) to Gilead Sciences Inc. for antiviral drug Veklury (remdesivir) to treat certain non-hospitalized adults and pediatric patients with mild-to-moderate COVID-19 disease.
RELATED NEWS
Follow RTT